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Summary
Background  and  methods:  The  CHA2DS2-VASc  score  has  been  newly  proposed  for  stratifying
patients  with  nonvalvular  atrial  ﬁbrillation  (AF)  according  to  the  risk  of  ischemic  stroke  in  the
2010 European  Society  of  Cardiology  guideline.  However,  there  is  little  information  about  its
usefulness  for  predicting  long-term  prognosis  of  cardiovascular  events  in  Japanese  patients
with paroxysmal  AF.  This  study  retrospectively  included  332  paroxysmal  AF  patients  (224  men,
mean age  65  ±  13  years,  mean  follow-up  period  53  ±  35  months)  without  receiving  anticoagulant
therapy between  June  1995  and  August  2008  who  were  categorized  into  risk  stratiﬁcation  on
the basis  of  CHA2DS2-VASc  score.
Results:  The  distribution  of  CHA2DS2-VASc  scores  was  0,  1,  2,  3,  4,  5,  6,  and  7  points  in  76  (23%),
60 (18%),  69  (21%),  69  (21%),  28  (8%),  23  (7%),  6  (2%),  and  1  (0.3%)  patients,  respectively.  The
annual rates  of  symptomatic  ischemic  stroke  were  0%,  0.60%,  0.95%,  1.96%,  5.45%,  9.06%,  and
13.7% when  the  CHA2DS2-VASc  score  was  0,  1,  2,  3,  4,  5,  and  ≥6  points,  respectively  (p  <  0.001)
and those  of  cardiovascular  events  including  hospitalization  for  thromboembolism,  heart  failure
and cardiovascular  death  were  0%,  1.43%,  1.50%,  2.52%,  10.14%,  12.85%,  and  17.13%  when  the
CHA2DS2-VASc  score  was  0,  1,  2,  3,  4,  5  and  ≥6  points,  respectively  (p  <  0.001).  Higher  CHA2DS2-
VASc scores  were  associated  with  greater  annual  rates  of  ischemic  stroke  and  cardiovascular
events.  In  a  multivariate  logistic  regression  analysis  adjusted  for  the  potentially  confounding
variables,  the  CHA2DS2-VASc  score  was  associated  with  symptomatic  ischemic  stroke  (odds  ratio
7.051, 95%  conﬁdence  interval  3.76—13.22,  p  <  0.001)  and  cardiovascular  events  (odds  ratio
3.448, 95%  conﬁdence  interval  2.33—5.11,  p  <  0.001).
∗ Corresponding author at: 19-1 Uchimaru, Morioka, Iwate 020-5805, Japan. Tel.: +81 19 651 5111x2324; fax: +81 19 651 0401.
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Conclusion:  In  Japanese  patients  with  paroxysmal  AF,  the  CHA2DS2-VASc  score  is  a  useful  scheme
for risk  stratiﬁcation  of  ischemic  stroke  and  cardiovascular  events.
© 2012  Japanese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All  rights  reserved.
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blood  was  collected  from  an  upper  limb  after  the  patient
had  rested  in  the  supine  position  if  no  palpitations  had  been
noted  since  the  start  of  drug  therapy  and  sinus  rhythm  wasntroduction
pidemiological  studies  in  Western  countries  indicate  that
he  incidence  of  atrial  ﬁbrillation  (AF)  increases  signiﬁcantly
ith  age,  occurring  in  approximately  4%  of  those  in  their  70s
nd  in  approximately  10%  of  those  over  the  age  of  80  years
1].  The  Japanese  elderly  population  is  swelling  rapidly,  and
he  incidence  of  AF  in  people  in  their  60s  and  70s  currently
tands  at  about  1%  and  2—3%,  respectively.  These  numbers
re  comparable  to  those  observed  in  Western  countries.  The
umber  of  patients  with  AF  in  2010  was  expected  to  reach
000  per  100,000  [2].  The  incidence  of  AF  is  expected  to
ontinue  increasing,  making  AF  one  of  the  major  illnesses
onfronting  medicine  today.
A  commonly  encountered  disease  in  routine  care,  AF
auses  not  just  cardiovascular  complications,  such  as  throm-
oembolism  or  heart  failure  [3],  but  can  present  as  a  type
f  life-threatening  arrhythmia  in  patients  with  left  ventric-
lar  dysfunction  [4].  AF  is  recognized  as  a  disease  that
ust  be  treated  and  managed  vigorously.  The  guidelines
ublished  in  2010  by  the  European  Society  of  Cardiology  rec-
mmend  that  risk  stratiﬁcation  for  ischemic  stroke,  a  serious
omplication  in  patients  with  nonvalvular  AF,  be  performed
ased  on  CHA2DS2-VASc  scores  to  administer  antithrom-
otic  treatment  accordingly  [5].  However,  it  remains  unclear
hether  CHA2DS2-VASc  scores  are  available  for  management
f  antithrombotic  treatment  in  Japanese  patients  with  non-
alvular  and  paroxysmal  AF.
Here,  we  retrospectively  investigated  the  incidence  of
schemic  stroke  and  cardiovascular  events  on  the  basis  of
HA2DS2-VASc  scores  in  patients  with  paroxysmal  AF  who
ere  not  administered  anticoagulation  therapy  before  the
apanese  Circulation  Society  (JCS)  issued  their  guidelines  in
008.
ethods
tudy  patients
efore  the  publication  of  the  Japanese  Circulation  Society
uidelines  in  2008,  of  the  505  patients  in  whom  paroxys-
al  AF  had  been  conﬁrmed  based  on  symptoms  and  12-lead
nd  ambulatory  24-h  monitoring  ﬁndings,  the  subjects  were
32  patients  (224  men  and  108  women;  average  age  of
5  ±  13  years)  not  receiving  anticoagulation  therapy,  in
hom  transthoracic  echocardiography  had  ruled  out  cardiac
alvular  disease.  All  subjects  were  treated  on  an  outpa-
ient  basis  every  two  to  four  weeks,  received  rhythm  control
herapy  using  antiarrhythmic  drugs,  and  were  followed  for
t  least  one  year.  In  all  patients,  fasting  blood  glucose
nd  hemoglobin  A1C  were  measured  to  screen  for  diabetes.
o  detect  underlying  cardiopulmonary  diseases,  noninva-
ive  tests,  including  history-taking,  chest  X-rays,  exercise
esting,  and  echocardiography,  were  performed.  Attending
c
t
a
whysicians  ordered  pulmonary  function  tests,  chest  com-
uted  tomography  (CT),  and  cardiac  catheterization,  if  this
as  considered  necessary.
The  study  excluded  patients  with  the  following  condi-
ions:  hepatorenal  dysfunction;  women  in  whom  pregnancy
as  likely;  or  patients  administered  warfarin  anticoagula-
ion  therapy.
eﬁnitions
aroxysmal  AF  was  deﬁned  as  AF  terminating  spontaneously
ithin  seven  days  of  onset  [6].  Permanent  (chronic)  AF  was
eﬁned  as  cases  of  AF  refractory  to  antiarrhythmic  drug
herapy  or  electrical  cardioversion  in  which  sinus  rhythms
ould  not  be  maintained  for  more  than  6  months,  as  assessed
y  electrocardiography  (ECG).  Cerebral  thromboembolism
as  conﬁrmed  based  on  clinical  symptoms  and  the  pres-
nce  of  a  ≥3-mm  infarct  area,  as  obtained  by  brain  CT
xamination  or  magnetic  resonance  imaging  (MRI).  Diag-
oses  of  hypertension  followed  the  2009  JSH  guidelines  [7].
yslipidemia  was  deﬁned  as  fasting  serum  cholesterol  of
220  mg/dl  and  triglycerides  of  ≥150  mg/dl  [8].  AF  was
ivided  into  three  types  as  follows,  depending  on  the  time
f  onset:  diurnal  type  (from  07:00  to  17:00);  nocturnal  type
from  17:00  to  07:00);  and  mixed  type  (anytime)  [9].  Car-
iovascular  events  were  deﬁned  as  any  of  the  following:
udden  death,  cardiac  failure,  or  ischemic  stroke.  Chronic
bstructive  pulmonary  disease  was  deﬁned  as  forced  expi-
atory  volume  in  one  second  of  <70%,  as  measured  by  a  lung
unction  test.
rotocols  and  antiarrhythmic  drug  therapy
ll  patients  received  rhythm  control  therapy  for  the  purpose
f  maintaining  sinus  rhythm.  The  efﬁcacy  of  antiarrhyth-
ic  drug  therapy  according  to  these  protocols  has  already
een  reported  in  detail  [10]. To  conﬁrm  the  recurrence  of
F,  symptoms  were  assessed  by  interview  and  a  standard
2-lead  ECG  was  recorded  after  starting  administration  of
ntiarrhythmic  drugs  or  at  2—4  weeks  after  changing  those
rugs,  while  an  ECG  was  recorded  with  a  portable  monitor
t  the  time  of  medical  examination.  Furthermore,  ambu-
atory  24-h  ECG  monitoring  was  performed  every  3  months
o  detect  recurrence  of  AF,  if  this  was  considered  neces-
ary  by  the  attending  physician.  For  measurement  of  human
trial  natriuretic  peptide  (ANP)  during  sinus  rhythm,  venousonﬁrmed  on  ECG  at  each  hospital  visit.  Whenever  palpita-
ions  occurred,  ambulatory  24-h  monitoring  was  conducted
t  the  discretion  of  the  attending  physician  to  determine
hether  AF  had  recurred  or  not.
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Figure  1  Distribution  of  CHA2DS2-VASc  scores  in  patients  with
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In  patients  whose  AF  became  permanent  despite  antiar-
rhythmic  drug  therapy,  either  -blockers,  Ca  antagonists,  or
digitalis  was  administered  orally  to  control  ventricular  rate.
Antithrombotic  therapy  protocols
Before  the  publication  of  the  Japanese  Circulation  Soci-
ety  guidelines  [11]  in  November  2001,  attending  physicians
administered  antithrombotic  therapy  at  their  own  discre-
tion.  After  November  2001,  antithrombotic  therapy  was
generally  performed  according  to  the  guidelines,  but  the
decision  to  administer  antithrombotic  therapy  was  left  to
the  physician.  Doses  of  aspirin  were  81—100  mg/day;  war-
farin  was  administered  according  to  guidelines  regulating
international  normalized  ratios  (target  INR:  1.6—3.0).
The  subjects  of  the  present  study  had  not  received
anticoagulation  therapy  or  had  received  only  aspirin.  We
examined  patient  distributions  in  relation  to  CHA2DS2-
VASc  scores,  patient  background  factors,  ischemic  stroke,
and  cardiovascular  events.  The  observation  period  for  the
present  study  was  June  1994  to  October  2008.  The  aver-
age  duration  of  the  observation  period  was  53  ±  35  months
(range:  12—127  months).
Statistical  analysis
In  the  present  study,  numerical  values  are  expressed  as
mean  ±  standard  deviation.  When  comparing  background
factors  among  patient  groups,  we  used  the  Mann—Whitney
U  test  for  statistical  analysis  and  the  2 test  for  compar-
ing  ratios.  We  applied  the  Kaplan—Meier  method  to  analyze
the  survival  rate  without  ischemic  stroke.  We  applied  the
log-rank  method  for  signiﬁcance  analysis  among  groups;
multivariate  logistic  analysis  to  predict  ischemic  stroke
and  cardiovascular  events;  and  the  Hosmer—Lemeshow
goodness-of-ﬁt  test  for  model  veriﬁcation.  We  used  the
SPSS  13.0  statistical  package  for  statistical  analyses,  with
level  of  signiﬁcance  set  to  p  <  0.05.  Cardiovascular  events
included  the  composite  of  hospitalization  for  thromboem-
bolism,  heart  failure,  and  cardiovascular  death.
Results
Distribution  of  CHA2DS2-VASc  scores  in  patients
with paroxysmal  AF
CHA2DS2-VASc  scores  were  distributed  as  follows:  0  points  in
76  patients  (23%);  1  point  in  60  patients  (18%);  2  points  in
69  patients  (21%);  3  points  in  69  patients  (21%);  4  points  in
28  patients  (8%);  5  points  in  23  patients  (7%);  and  ≥6  points
in  7  patients  (2%)  (Fig.  1).
Comparison  of  patient  background  factors  among
different CHA2DS2-VASc  score  groups
The  patients  differed  signiﬁcantly  among  different  CHA2DS2-
VASc  score  groups  with  respect  to  gender,  age,  hypertension,
diabetes,  history  of  alcohol  consumption,  and  asymp-
tomatic  AF  (p  <  0.05)  (Tables  1A  and  1B).  They  also
exhibited  signiﬁcant  differences  in  disease  duration,
5
g
H
aaroxysmal  atrial  ﬁbrillation.
enin—angiotensin—aldosterone  (RAAS)  inhibitor,  statin,
HADS2 scores,  and  aspirin  administration.  Seventy-nine
24%)  of  332  patients  had  underlying  heart  disease,  including
ld  myocardial  infarction  (n  =  15),  angina  pectoris  (n  =  20),
ilated  cardiomyopathy  (n  =  5),  hypertrophic  cardiomyopa-
hy  (n  =  13),  atrial  septal  defect  (n  =  2),  syndrome  X  (n  =  2),
yocarditis  (n  =  1),  and  sick  sinus  syndrome  (n  =  7).  On  the
ther  hand,  all  patients  were  administered  ﬁrst-line  drugs
or  rhythm  control  therapy,  including  disopyramide  (n  =  80),
prindine  (n  =  51),  cibenzoline  (n  =  101),  pilsicainide  (n  =  40),
ecainide  (n  =  25),  propafenone  (n  =  6),  pirmenol  (n  = 11),
epridil  (n  =  12),  amiodarone  (n  =  2),  verapamil  (n  =  1),  and
-blockers  (n  =  3).  However,  we  found  no  signiﬁcant  differ-
nces  in  underlying  heart  disease  or  types  of  antiarrhythmic
rugs  administered  among  different  CHA2DS2-VASc  score
roups.
urvival  rate  without  ischemic  stroke  among
ifferent CHA2DS2-VASc  score  groups
he  proportion  of  subjects  in  whom  ischemic  stroke  had  not
ccurred  at  observation  periods  of  12,  36,  60,  90,  and  120
onths  for  the  CHA2DS2-VASc  score  0-point  group  was  100%,
00%,  100%,  100%,  and  100%,  respectively;  for  the  1-point
roup,  100%,  100%,  98%,  98%,  and  97%,  respectively;  for  the
-point  group,  99%,  99%,  97%,  97%,  and  97%,  respectively;
or  the  3-point  group,  99%,  94%,  91%,  91%,  and  90%,  respec-
ively;  for  the  4-point  group,  96%,  93%,  89%,  79%,  and  75%,
espectively;  for  the  5-point  group,  96%,  78%,  70%,  52%,  and
8%,  respectively;  and  for  the  ≥6-point  group,  86%,  71%,
7%,  43%,  and  43%,  respectively  (Fig.  2).
nnual  rates  of  ischemic  stroke  among  different
HA2DS2-VASc  score  groups  without  receiving
nticoagulation  (warfarin)  therapy
he  annual  rates  of  ischemic  stroke  were  0%/year  for  the  0-
oint  group;  0.60%/year  for  the  1-point  group;  0.95%/year
or  the  2-point  group;  1.96%/year  for  the  3-point  group;
.45%/year  for  the  4-point  group;  9.06%/year  for  the  5-point
roup;  and  13.7%/year  for  the  ≥6-point  group  (p  <  0.001).
igher  CHA2DS2-VASc  scores  were  associated  with  greater
nnual  rates  of  ischemic  stroke.
324  T.  Komatsu  et  al.
Table  1A  Patient  proﬁles  among  different  CHA2DS2-VASc  score  groups.
CHA2DS2-VASc  score  0  1  2  3  4  5  ≤6  p-Value
Number  76  60  69  69  28  23  7
Observed periods  (months)  45  ±  33  42  ±  31  58  ±  34  62  ±  39  55  ±  32  69  ±  33  50  ±  29  0.342
Age (years)  51  ±  11  60  ±  9  69  ±  7  73  ±  8  74  ±  6  77  ±  7  78  ±  3  0.001
Male:female  57:19  47:13  49:20  36:33  18:10  16:7  1:6  0.001
Hypertension  0  (0%)  32  (53%)  32  (46%)  42  (61%)  18  (64%)  13  (57%)  5  (71%)  0.001
Diabetes mellitus  0  (0%)  7  (12%)  8  (12%)  11  (16%)  8  (29%)  7  (30%)  1  (14%)  0.001
Dyslipidemia 11  (14%)  5  (8%)  7  (10%)  17  (25%)  2  (7%)  1  (4%)  1  (14%)  0.057
Smoking 27 (36%) 16  (27%)  17  (25%)  16  (23%)  10  (36%)  4  (17%)  0  (0%)  0.410
Alcohol 40 (53%) 27  (45%) 29  (42%) 18  (26%) 12  (43%) 8  (35%) 0  (0%)  0.012
Hyperuricemia 3  (4%) 3  (5%) 4  (6%) 7  (10%) 1  (4%) 1  (4%) 0  (0%) 0.711
Underlying heart  disease 7  (9%) 13  (22%) 14  (20%) 16  (23%) 8  (29%) 7  (30%) 1  (14%) 0.117
Underlying pulmonary  disease  2  (3%)  4  (7%)  5  (7%)  3  (4%)  4  (14%)  0  (0%)  0  (0%)  0.242
Asymptomatic  AF  4  (5%)  4  (7%)  6  (9%)  12  (17%)  5  (18%)  6  (26%)  1  (14%)  0.040
Table  1B  Patient  proﬁles  among  different  CHA2DS2-VASc  score  groups.
CHA2DS2-VASc  score 0 1 2 3  4  5  ≤6  p-Value
Number 76 60  69  69  28  23  7
AF history  (months) 19  ±  31 12  ±  28 23  ±  33  17  ±  30  11  ±  17  24  ±  54  10  ±  10  0.001
LVDd (mm) 46  ±  5 46  ±  6  47  ±  6  45  ±  6  45  ±  5  46  ±  6  47  ±  5  0.312
LAD (mm) 33  ±  7 35  ±  7 34  ±  7  35  ±  6  34  ±  6  36  ±  6  36  ±  4  0.147
LVEF (%) 70  ±  10 69  ±  10 70  ±  8 69  ±  11  67  ±  8  67  ±  15  61  ±  13  0.195
RAAS inhibitors 3  (4%) 13  (22%) 17  (25%) 24  (35%) 13  (46%)  6  (26%)  4  (57%)  0.001
Statin 11 (14%) 5  (8%)  7  (10%)  18  (26%)  2  (7%)  1  (4%)  1  (14%)  0.029
CHADS2 score  0 0.6  ±  0.5 0.9  ±  0.6  1.6  ±  0.6  2.5  ±  0.5  3.6  ±  0.5  4.0  ±  0.6  0.001
Antithrombotic  therapy
None 63  (83%) 44  (73%) 44  (64%) 46  (67%) 12  (43%)  10  (43%)  2  (29%)  0.001
Aspirin 13  (17%)  16  (27%)  25  (36%)  23  (33%)  16  (57%)  13  (57%)  5  (71%)  0.001
Warfarin —  —  —  —  —  —  —
At registration
ANP  during  SR  (pg/ml)  29  ±  42  46  ±  50  37  ±  37  39  ±  25  49  ±  35  37  ±  20  85  ±  35  0.106
Onset of  AF
Diurnal:nocturnal:mixed  6:46:24  15:24:21  14:23:32  19:25:25  5:5:18  6:4:13  0:2:5  0.207
Continuous values are the mean ± SD. Values in parentheses are %.
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RAAS, renin—angiotensin—aldosterone system; ANP, atrial naturiu
redictors  for  ischemic  stroke  in  patients  with
aroxysmal AF
n  a  multivariate  logistic  regression  analysis  adjusted
or  other  potentially  confounding  variables,  CHA2DS2-
ASc  scores  (odds  ratio:  7.05,  95%  conﬁdence  interval:
.76—13.22,  and  p  <  0.001)  and  mixed-type  onset  (odds
atio:  5.39,  95%  conﬁdence  interval:  1.49—19.51  and
 =  0.010)  were  signiﬁcant  independent  predictors  for
schemic  stroke  (Table  2).
urvival  rate  without  cardiovascular  events  among
ifferent CHA2DS2-VASc  score  groupshe  proportion  of  subjects  in  whom  cardiovascular  events
ad  not  occurred  at  observation  periods  of  12,  36,  60,  90,
nd  120  months  for  the  CHA2DS2-VASc  score  0-point  group
T
f
1
gD, left atrial dimension; LVEF, left ventricular ejection fraction;
peptide; SR, sinus rhythm.
as  100%,  100%,  99%,  99%,  and  99%,  respectively;  for  the
-point  group,  98%,  97%,  95%,  93%,  and  93%,  respectively;
or  the  2-point  group,  99%,  99%,  96%,  94%,  and  93%,  respec-
ively;  for  the  3-point  group,  97%,  91%,  88%,  86%,  and  81%,
espectively;  for  the  4-point  group,  93%,  86%,  68%,  64%,  and
4%,  respectively;  for  the  5-point  group,  87%,  70%,  48%,  35%,
nd  30%,  respectively;  and  for  the  ≥6-point  group,  71%,  57%,
3%,  14%,  and  14%,  respectively  (Fig.  3).
nnual  rates  of  cardiovascular  events  among
ifferent CHA2DS2-VASc  score  groups  without
eceiving anticoagulation  (warfarin)  therapyhe  annual  rates  of  cardiovascular  events  were  0%/year
or  the  0-point  group;  1.43%/year  for  the  1-point  group;
.50%/year  for  the  2-point  group;  2.52%/year  for  the  3-point
roup;  10.14%/year  for  the  4-point  group;  12.85%/year  for
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Figure  2  Survival  curve  without  ischemic  stroke  among  different  CHA2DS2-VASc  score  groups.
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the  5-point  group;  and  17.13%/year  for  the  ≥6-point  group
(p  <  0.001).  Once  again,  higher  CHA2DS2-VASc  scores  corre-
lated  with  greater  annual  rates  of  cardiovascular  events.
Predictors  for  cardiovascular  events  in  patients
with paroxysmal  AF
In  a  multivariate  logistic  regression  analysis  adjusted
for  other  potentially  confounding  variables,  CHA2DS2-VASc
scores  (odds  ratio:  3.45;  95%  conﬁdence  interval:  2.33—5.11;
p  <  0.001),  left  ventricular  ejection  fractions  (odds  ratio:
0.94;  95%  conﬁdence  interval:  0.90—0.97;  p  <  0.001),  and
permanent  AF  (odds  ratio:  4.88;  95%  conﬁdence  interval:
c
p
l
ants  among  different  CHA2DS2-VASc  score  groups.
.70—14.1;  p  =  0.003)  were  signiﬁcant  independent  predic-
ors  of  cardiovascular  events  (Table  3).
iscussion
ajor  points
he  present  study  found  that  higher  CHA2DS2-VASc  scores
orrelated  with  higher  annual  rates  of  ischemic  stroke  for
aroxysmal  AF  patients  not  receiving  warfarin  anticoagu-
ation  therapy.  The  CHA2DS2-VASc  score  also  proved  to  be
n  independent  predictor  of  ischemic  stroke.  Additionally,
326  
Table  2  Predictors  for  ischemic  stroke  in  patients  with
paroxysmal  atrial  ﬁbrillation.
Variables  Odds  ratio  (95%CI)  p-Value
CHA2DS2-VASc  score  7.051  (3.759—13.22)  0.001
Mixed type  (onset  of  AF)  5.391  (1.490—19.51)  0.010
RAAS inhibitors  3.422  (0.993—11.80)  0.051
Statins 3.845  (0.803—18.41)  0.092
Underlying  pulmonary
disease
2.869  (0.412—19.96)  0.287
AF history  (months) 1.005  (0.991—1.019) 0.503
LAD (mm) 1.030  (0.938—1.131) 0.534
Conversion  to  Chronic
AF
1.356  (0.375—4.903)  0.642
Underlying  heart  disease  1.098  (0.306—3.948)  0.886
AF recurrence  1.079  (0.289—4.028)  0.910
LVDd (mm)  1.002  (0.903—1.111)  0.975
LVEF (%)  1.001  (0.952—1.051)  0.990
Multivariate logistic regression analysis adjusted for age and sex.
AF, atrial ﬁbrillation; LAD, left atrial dimension; LVDd, left ven-
tricular end-diastolic dimension, LVEF, left ventricular ejection
fraction; RAAS; renin—angiotensin—aldosterone system.
Table  3  Predictors  for  cardiovascular  events  in  patients
with paroxysmal  atrial  ﬁbrillation.
Variables  Odds  ratio  (95%CI)  p-Value
CHA2DS2-VASc  score  3.448  (2.328—5.107)  0.001
LVEF (%)  0.936  (0.899—0.973)  0.001
Conversion  to  Chronic
AF
4.881  (1.696—14.05)  0.003
Mixed type  (onset  of  AF)  2.313  (0.917—5.834)  0.076
LAD (mm)  0.954  (0.892—1.021)  0.174
Underlying  pulmonary
disease
2.681  (0.568—12.66)  0.213
AF history  (months)  1.005  (0.992—1.019)  0.418
RAAS inhibitors 1.291  (0.527—3.165)  0.576
Underlying  heart  disease 1.239  (0.510—3.006)  0.636
Statins 1.287  (0.393—4.210)  0.677
LVDd (mm)  1.006  (0.932—1.086)  0.876
AF recurrence  1.060  (0.394—2.850)  0.908
Multivariate logistic regression analysis adjusted for age and sex.
AF, atrial ﬁbrillation; LAD, left atrial dimension; LVDd, left ven-
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Atricular end-diastolic dimension; LVEF, left ventricular ejection
fraction; RAAS, renin—angiotensin—aldosterone system.
igher  CHA2DS2-VASc  scores  correlated  with  higher  rates  of
ardiovascular  events  that  are  composite  events  of  cardio-
ascular  death,  heart  failure,  and  ischemic  stroke.  Likewise,
he  CHA2DS2-VASc  score  was  an  independent  predictor  of
ardiovascular  prognosis  for  paroxysmal  AF  patients.
HA2DS2-VASc  scores  for  stratifying  risk  of
ardiogenic cerebral  embolism  in  nonvalvular  AF
atientsarge-scale  clinical  studies  in  Western  countries  indicate  the
nnual  rates  of  ischemic  stroke  in  nonvalvular  AF  patients
anges  from  3%  to  6.3%  [12—17]. Japanese  clinical  studies
o
i
e
AT.  Komatsu  et  al.
how  annual  rates  of  ischemic  stroke  in  nonvalvular  AF
atients  of  2.8—4.5%  [18,19].  The  latter  ﬁgures  are  not  nec-
ssarily  lower  than  those  observed  in  Western  countries.
he  2010  ESC  guidelines  added  age  (from  65  to  74  years)
20],  vascular  disease  [21], and  gender  (female)  [22]  as  risk
actors  for  ischemic  stroke.  The  CHA2DS2-VASc  score  has
ecently  been  added  as  a  new  scheme  for  risk  stratiﬁcation.
 large-scale  European  study  showed  a  close  correlation
etween  high  CHA2DS2-VASc  scores  and  high  annual  rates
f  ischemic  stroke  [23]. Guidelines  for  preventing  ischemic
troke  recommend  aspirin  or  anticoagulation  therapy  for
atients  with  CHA2DS2-VASc  scores  of  1  point  and  antico-
gulation  therapy  for  all  patients  with  CHA2DS2-VASc  scores
f  ≥2  points.  However,  to  the  best  of  our  knowledge,  no
apanese  studies  have  reported  on  the  useful  scheme  of
HA2DS2-VASc  scores  for  stratifying  risk  of  ischemic  stroke
n  patients  with  AF.
In the  present  study,  an  investigation  of  the  distribu-
ion  of  CHA2DS2-VASc  scores  in  patients  with  paroxysmal  AF
howed  that  low-risk  patients  at  0  or  1  points  accounted
or  about  40%  of  the  total,  a  signiﬁcant  difference  from
he  J-RHYTHM  study  (a  prospective  multicenter  compara-
ive  study  performed  ﬁve  years  ago)  [24]  in  which  low-risk
atients  with  CHADS2 scores  of  0  or  1  points  accounted  for
bout  90%  of  the  subjects.  This  suggests  that  AF  patients
ith  risk  factors  for  ischemic  stroke  are  increasing,  which
n  turn  indicates  that  patient  background  factors  for  AF  in
apanese  patients  are  approaching  those  in  patients  in  the
SA  and  Europe.  No  general  consensus  has  been  reached
n  the  threshold  value  for  antithrombotic  drug  therapy  in
atients  with  AF.  In  particular,  there  is  active  debate  regard-
ng  anticoagulation  therapy  for  moderate  risk  patients.
ome  researchers  recommend  active  administration  of  anti-
oagulation  therapy  [25], while  others  advocate  focusing  on
atient  wishes  and  individual  bleeding  risks  [26]. We  previ-
usly  investigated  the  annual  rate  of  ischemic  stroke  with
espect  to  CHADS2 scores  [27]. In  general,  the  annual  rate  of
schemic  stroke  for  patients  with  CHADS2 scores  of  ≥2  points
as  comparable  to  those  reported  in  studies  published  in
he  USA  and  Europe,  supporting  the  validity  of  the  2008
apanese  Circulation  Society  guidelines  on  use  of  anticoag-
lation  therapy  in  patients  with  AF.  The  2010  ESC  guidelines
dded  new  risk  factors  for  ischemic  stroke,  closely  exam-
ning  the  question  of  whether  antithrombotic  drug  therapy
hould  be  indicated  for  low  and  moderate  risk  patients  with
HADS2 scores  of  0  or  1.  The  results  of  the  present  study
howed  that  the  annual  rates  of  ischemic  stroke  in  parox-
smal  AF  patients  at  ≥3  CHA2DS2-VASc  points  in  Japan  are
imilar  to  Western  countries,  suggesting  the  need  to  explore
he  use  of  anticoagulation  therapy  for  these  patients  since
hey  have  at  least  moderate  risk.
HA2DS2-VASc  scores  for  risk  stratiﬁcation  of
ardiovascular events  in  patients  with  nonvalvular
F
ccording  to  certain  single-center  studies  in  Japan,  the  rate
f  cardiovascular  mortality  in  patients  with  paroxysmal  AF
s  approximately  0.7—0.9%  [10,28].  No  signiﬁcant  differ-
nces  were  found  between  paroxysmal  and  persistent  AF.
 meta-analysis  of  a  large-scale  multicenter  comparative
illati
R
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[CHA2DS2-VASc  scores  in  patients  with  paroxysmal  atrial  ﬁbr
study  (AFFIRM)  in  a  Western  country  showed  that  AF  type
(paroxysmal  or  persistent)  did  not  signiﬁcantly  affect  cardio-
vascular  prognosis  for  each  AF  patient,  while  independent
predictors  were  factors  including  age,  diabetes,  underly-
ing  heart  disease,  complications  involving  heart  failure  or
ischemic  stroke,  sinus  rhythm  maintenance,  and  warfarin-
based  anticoagulation  therapy  [29]. We  reported  that  in
a  follow-up  of  patients  for  about  50  months,  left  ventric-
ular  ejection  fraction,  conversion  to  permanent  AF,  and
anticoagulation  therapy  are  independent  predictors  of  car-
diovascular  prognosis  following  antiarrhythmic  drug  therapy
in  patients  with  AF  [30]. However,  research  remains  inade-
quate  on  the  indicators  that  may  be  used  to  assess  prognosis
more  conveniently.  In  the  present  study,  where  cardiovas-
cular  events  were  deﬁned  as  cardiovascular  death,  heart
failure,  or  ischemic  stroke,  the  annual  rate  of  cardiovascu-
lar  events  in  patients  with  scores  of  ≥4  for  CHA2DS2-VASc
(≥4-point  group)  exceeded  10%,  indicating  clearly  their  sta-
tus  as  a  high-risk  group.  The  present  study  also  showed
that  in  Japanese  patients  with  paroxysmal  AF,  the  CHA2DS2-
VASc  score  is  an  independent  predictor  not  only  of  ischemic
stroke,  but  also  cardiovascular  prognosis.  This  conﬁrms  that
the  CHA2DS2-VASc  is  a  useful  scheme  for  managing  paroxys-
mal  AF  patients.  To  improve  the  prognosis  for  paroxysmal
AF  patients,  we  must  continue  to  investigate  the  efﬁ-
cacy  of  pharmacological  or  non-pharmacological  therapies
in  patients  with  high  CHA2DS2-VASc  scores.
Limitations
This  study  has  the  following  limitations:  (1)  since  the  study  is
retrospective  and  observational,  it  reﬂects  biases  in  patient
backgrounds  among  the  groups.  (2)  All  subjects  received
rhythm  control  therapy  to  maintain  sinus  rhythms,  and  the
results  of  rate  control  therapy  could  not  be  elucidated.  How-
ever,  large-scale  comparative  studies  in  Western  countries
[31,32]  indicate  no  signiﬁcant  differences  in  the  incidence
of  ischemic  stroke  or  in  cardiovascular  prognosis  between
rhythm  control  therapy  and  rate  control  therapy.  (3)  The
present  study  included  only  paroxysmal  AF  patients.  We
could  not  identify  therapeutic  efﬁcacy  in  patients  with  per-
sistent  or  permanent  AF.  However,  the  SPAF  study  reported
no  signiﬁcant  differences  in  the  annual  rate  of  ischemic
stroke  between  cases  of  paroxysmal  AF  and  permanent  AF
[17].  (4)  We  did  not  evaluate  the  relationship  between
ischemic  stroke  and  systemic  inﬂammation  as  indicated  by
C-reactive  protein  [33]. (5)  The  number  of  patients  with
higher  CHA2DS2-VASc  scores  was  relatively  small.  A  large-
scale  multicenter  study  should  be  performed  in  Japanese
patients  with  AF  to  evaluate  the  relationship  between
CHA2DS2-VASc  scores  and  cardiovascular  events.
Conclusion
Among  Japanese  patients  with  paroxysmal  AF,  higher
CHA2DS2-VASc  scores  were  revealed  to  be  associated  with
higher  annual  rates  of  ischemic  stroke  and  cardiovascular
events.  These  results  also  indicated  that  the  CHA2DS2-VASc
score  is  a  useful  scheme  for  managing  cardiovascular  prog-
nosis  in  patients  with  paroxysmal  AF.
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